Targets, structures, and recent approaches in malignant melanoma chemotherapy.

about

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors Structure-Activity Relationships within a Series of σ1 and σ2 Receptor Ligands: Identification of a σ2 Receptor Agonist (BS148) with Selective Toxicity against Metastatic Melanoma.

P2860

Q26852274-FC6C28CE-2D2F-4B2B-9B6D-80326BA58D7E Q47756273-19B7B72A-A264-46C2-9E85-E163CF078ACA

P2860

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

Item

http://www.wikidata.org/entity/Q38129832

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

@en

type

Item

label

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

@en

prefLabel

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

@en

P1476

Targets, structures, and recent approaches in malignant melanoma chemotherapy

@en

P2093

Ana Marta Matos

http://www.w3.org/2001/XMLSchema#string

P2860

Main roads to melanoma

Hallmarks of Cancer: The Next Generation

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes

Back to the roots: the remarkable RAF oncogene story

Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

P304

1751-1765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201300248

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ana Paula Francisco

P577

2013-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23956078

http://www.w3.org/2001/XMLSchema#string

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

about

P2860

P2860

Targets, structures, and recent approaches in malignant melanoma chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698